Chimeric Antig en Receptor T-cell (CAR T) therapy has revolutionized the treatment of certain hematological malignancies, offering hope for patients with refractory or relapsed cancers. As the use of CAR T cells becomes more widespread, effective methods for monitoring and detecting these engineered cells are critical for optimizing therapy and ensuring patient safety.

The Carl June Lab has once again advanced the frontiers of immunotherapy research with their recently published study, “Stem Loop Mediated Transgene Modulation in Human T Cells” featured in ACS Synthetic Biology.

Johnson & Johnson has just released their 2024 Annual Report, showcasing remarkable progress for Carvykti (cilta-cel), the revolutionary CAR T-cell therapy for relapsed or refractory multiple myeloma.